378 related articles for article (PubMed ID: 23537510)
1. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
2. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
3. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
4. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
5. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
6. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
Christadoss P; Tüzün E; Li J; Saini SS; Yang H
Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
[TBL] [Abstract][Full Text] [Related]
7. Targeting complement system to treat myasthenia gravis.
Huda R; Tüzün E; Christadoss P
Rev Neurosci; 2014; 25(4):575-83. PubMed ID: 24731953
[TBL] [Abstract][Full Text] [Related]
8. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
9. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
[TBL] [Abstract][Full Text] [Related]
10. IgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c mice.
Huda R; Strait RT; Tüzün E; Finkelman FD; Christadoss P
J Neuroimmunol; 2015 Apr; 281():68-72. PubMed ID: 25867470
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in Mice.
Theissen L; Schroeter CB; Huntemann N; Räuber S; Dobelmann V; Cengiz D; Herrmann A; Koch-Hölsken K; Gerdes N; Hu H; Mourikis P; Polzin A; Kelm M; Hartung HP; Meuth SG; Nelke C; Ruck T
Cells; 2024 Mar; 13(6):. PubMed ID: 38534352
[TBL] [Abstract][Full Text] [Related]
12. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
13. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
14. The role of complement in experimental autoimmune myasthenia gravis.
Kusner LL; Kaminski HJ
Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
[TBL] [Abstract][Full Text] [Related]
15. Cell surface complement regulators moderate experimental myasthenia gravis pathology.
Kusner LL; Halperin JA; Kaminski HJ
Muscle Nerve; 2013 Jan; 47(1):33-40. PubMed ID: 23042232
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
Biesecker G; Gomez CM
J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
[TBL] [Abstract][Full Text] [Related]
17. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
[TBL] [Abstract][Full Text] [Related]
18. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
[TBL] [Abstract][Full Text] [Related]
19. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
20. Targeting classical complement pathway to treat complement mediated autoimmune diseases.
Tüzün E; Li J; Saini SS; Yang H; Christadoss P
Adv Exp Med Biol; 2008; 632():265-72. PubMed ID: 19025128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
